Top

Published in:

01-11-2007

Differential Contribution of the CysLTR1 Gene in Patients with Aspirin Hypersensitivity

Authors: Seung-Hyun Kim, Eun-Mi Yang, Han-Jung Park, Young-Min Ye, Hyun-Young Lee, Hae-Sim Park

Published in: Journal of Clinical Immunology | Issue 6/2007

Abstract

In this study, we compared the roles of CysLT receptor type 1 (CysLTR1) and leukotriene C4 synthase (LTC4S) gene polymorphisms in two major aspirin-related allergic diseases, aspirin-intolerant asthma (AIA) and aspirin-induced chronic urticaria/angioedema (AICU). CysLTR1-634C>T and LTC4S-444A>C polymorphisms were genotyped and its functional effect on the promoter activity was compared. As in vivo functional study, changes of peripheral mRNA level of CysLTR1 were measured by real-time PCR before and after aspirin challenge. A significant association was found for the CysLTR1 promoter polymorphism and the AIA phenotype compared to AICU (P = 0.015). In U937 cells, the variant genotype reporter construct showed significantly higher promoter activity than the common genotype (P < 0.05). The CysLTR1 mRNA levels increased significantly after aspirin challenge in AIA patients (P = 0.013). In conclusion, the CysLTR1 polymorphism may contribute to develop to the AIA phenotype and be used as a genetic marker for differentiating two major aspirin hypersensitivity phenotypes.

Simon RA. Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep 2004;4:17–24.PubMedCrossRef

Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003;111:913–21.PubMedCrossRef

Stevenson DD. Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am 2004;24:491–505.PubMedCrossRef

Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990;3:588–93.PubMed

Park HS, Cho YH, Kim SS, Kim HY, Nahm DH, Suh CH, et al. Prevalence of sensitivity to aspirin (ASA) and food additives in subjects diagnosed as having intrinsic asthma. J Asthma Allergy Clin Immunol 1998;18:662–71.

Ye YM, Kim JE, Kim SH, Suh CH, Nahm DH, Park HS. Clinical characteristics of chronic urticaria with aspirin sensitivity. J Asthma Allergy Clin Immunol 2005;25:194–9.

Dahlen SE, Malmstrom K, Nizankowska E, Dahlen B, Kuna P, Kowalski M, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:9–14.PubMed

Obase Y, Shimoda T, Tomari SY, Mitsuta K, Kawano T, Matsuse H, et al. Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients. Chest 2002;121:143–50.PubMedCrossRef

Mastalerz L, Setkowicz M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol 2004;113:771–5.PubMedCrossRef

10.

Nettis E, Di PR, Ferrannini A, Tursi A. Tolerability of Rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002;88:331–4.PubMedCrossRef

11.

Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol 2003;139:1577–82.PubMedCrossRef

12.

Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 2003;111:S18–36.PubMedCrossRef

13.

Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871–5.PubMedCrossRef

14.

Foegh ML, Hecker M, Ramwell PW. The eicosanoids: prostaglandins, thromboxanes, leukotrienes, and related compounds. In: Katzung BG, editor. Basic and clinical pharmacology. 5th ed. Connecticut: Appleton and Lange; 1998. p. 304–18.

15.

Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997;350:1599–600.PubMedCrossRef

16.

Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000;23:290–6.PubMed

17.

Mastalerz L, Setkowicz M, Sanak M, Rybarczyk H, Szczeklik A. Familial aggregation of aspirin-induced urticaria and leukotriene C synthase allelic variant. Br J Dermatol 2006;154:256–60.PubMedCrossRef

18.

Lynch KR, O’Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999;399:789–93.PubMedCrossRef

19.

Kim SH, Oh JM, Kim YS, Palmer LJ, Suh CH, Nahm DH, et al. CysLTRI promoter polymorphism is associated with aspirin-intolerant asthma in males. Clin Exp Allergy 2006;36:433–9.PubMedCrossRef

20.

Penrose JF, Spector J, Baldasaro M, Xu K, Boyce J, Arm JP, et al. Molecular cloning of the gene for human leukotriene C4 synthase: organization, nucleotide sequence, and chromosomal localization to 5q35. J Mol Chem 1996;271:11356–61.

21.

Kawagishi Y, Mita H, Taniguchi M, Maruyama M, Oosaki R, Higashi N, et al. Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 2002;109:936–42.PubMedCrossRef

22.

Van Sambeek R, Stevenson DD, Baldasaro M, Lam BK, Zhao J, Yoshida S, et al. 5′ flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J Allergy Clin Immunol 2000;106:72–6.PubMedCrossRef

23.

Choi JH, Kim SH, Bae JS, Yu HL, Suh CH, Nahm DH, et al. Lack of an association between a new LTC4S promoter polymorphism (-1702G>A) and aspirin-intolerant asthma (AIA) in a Korean population. Tohoku J Exp Med 2006;208:49–56.PubMedCrossRef

24.

Kim SH, Choi JH, Holloway JW, Suh CH, Nahm DH, Ha EH, et al. Leukotriene-related gene polymorphisms in patients with ASA-induced urticaria and ASA-intolerant asthma: differing contributions of ALOX5 polymorphism in Korea population. J Korean Med Sci 2005;20:926–31.PubMedCrossRef

25.

Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002;347:1493–9.PubMedCrossRef

Title: Differential Contribution of the CysLTR1 Gene in Patients with Aspirin Hypersensitivity
Authors: Seung-Hyun Kim
Eun-Mi Yang
Han-Jung Park
Young-Min Ye
Hyun-Young Lee
Hae-Sim Park
Publication date: 01-11-2007
Publisher: Springer US
Published in: Journal of Clinical Immunology / Issue 6/2007
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-007-9115-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2007

The Phenomenon of Spontaneous Genetic Reversions in the Wiskott-Aldrich Syndrome: A Report of the Workshop of the ESID Genetics Working Party at the XIIth Meeting of the European Society for Immunodeficiencies (ESID). Budapest, Hungary October 4–7, 2006

Carboxypeptidase D: A Novel TGF-β Target Gene Dysregulated in Patients with Lupus Erythematosus

Contiguous X-chromosome Deletion Syndrome Encompassing the BTK, TIMM8A, TAF7L, and DRP2 Genes

Apoptosis Inhibitor Expressed by Macrophages Tempers Autoimmune Colitis and the Risk of Colitis-Based Carcinogenesis in TCRα−/− Mice

A Multicenter, Prospective, Open Label, Historically Controlled Clinical Trial to Evaluate Efficacy and Safety in Primary Immunodeficiency Diseases (PID) Patients of Flebogamma® 5% DIF, the Next Generation of Flebogamma®

Enhanced In Vivo Protein Synthesis in Circulating Immune Cells of ICU Patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials